Abstract
Objectives: Epithelial ovarian cancer (EOC) patients with BRCA 1 or 2 mutations (gBRCA) have been shown to have a better prognosis including longer progression free intervals and high response rates to platinum–based therapy compared with patients who are BRCA wild type (wtBRCA). This has been attributed to homologous-recombination repair deficiency in the absence of BRCA1/2 function leading to increased tumor sensitivity to chemotherapy. This frequency matched case control study evaluated the impact on progression free survival (PFS) of intraperitoneal chemotherapy (IPC) and bevacizumab (BEV) during primary treatment among patients with gBRCA and wtBRCA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
